CanSino Biologics, Inc. Class H (HK:6185) has released an update.
CanSino Biologics, Inc. reported a significant increase in operating revenue for the first nine months of 2024, reaching over 263 million RMB, marking a 76% rise compared to the same period in 2023. However, the company faced financial challenges with a net loss of approximately 222 million RMB, demonstrating a need for strategic adjustments moving forward. Investors should remain cautious despite the revenue growth due to the substantial net losses reported.
For further insights into HK:6185 stock, check out TipRanks’ Stock Analysis page.
